Chiarle Roberto, Voena Claudia, Ambrogio Chiara, Piva Roberto, Inghirami Giorgio
Center for Experimental Research and Medical Studies (CERMS), University of Torino, Via Santena 7, 10126, Italy.
Nat Rev Cancer. 2008 Jan;8(1):11-23. doi: 10.1038/nrc2291.
Tyrosine kinases are involved in the pathogenesis of most cancers. However, few tyrosine kinases have been shown to have a well-defined pathogenetic role in lymphomas. The anaplastic lymphoma kinase (ALK) is the oncogene of most anaplastic large cell lymphomas (ALCL), driving transformation through many molecular mechanisms. In this Review, we will analyse how translocations or deregulated expression of ALK contribute to oncogenesis and how recent genetic or pharmacological tools, aimed at neutralizing its activity, can represent the basis for the design of powerful combination therapies.
酪氨酸激酶参与了大多数癌症的发病机制。然而,很少有酪氨酸激酶在淋巴瘤中被证明具有明确的致病作用。间变性淋巴瘤激酶(ALK)是大多数间变性大细胞淋巴瘤(ALCL)的致癌基因,通过多种分子机制驱动细胞转化。在本综述中,我们将分析ALK的易位或表达失调如何促进肿瘤发生,以及旨在中和其活性的最新基因或药理学工具如何能够成为设计有效联合疗法的基础。